Published in Clin Infect Dis on September 01, 2009
Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med (2011) 2.98
Neurocognitive and motor deficits in HIV-infected Ugandan children with high CD4 cell counts. Clin Infect Dis (2012) 1.97
HIV-associated neurocognitive disorder. Lancet Infect Dis (2013) 1.60
HIV transmission. Cold Spring Harb Perspect Med (2012) 1.52
HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment. Cold Spring Harb Perspect Med (2012) 1.34
Current understanding of HIV-associated neurocognitive disorders pathogenesis. Curr Opin Neurol (2011) 1.29
Pathogenesis of HIV in the central nervous system. Curr HIV/AIDS Rep (2011) 1.26
Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. Virology (2012) 1.18
A conserved determinant in the V1 loop of HIV-1 modulates the V3 loop to prime low CD4 use and macrophage infection. J Virol (2010) 1.17
HIV-subtype A is associated with poorer neuropsychological performance compared with subtype D in antiretroviral therapy-naive Ugandan children. AIDS (2010) 1.16
HIV-1 phylogenetic analysis shows HIV-1 transits through the meninges to brain and peripheral tissues. Infect Genet Evol (2010) 1.12
HIV-1 Genetic Variability and Clinical Implications. ISRN Microbiol (2013) 1.10
Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study a5199, the International Neurological Study. Clin Infect Dis (2012) 1.08
Neurocognitive impairment in HIV-1 clade C- versus B-infected individuals in Southern Brazil. J Neurovirol (2013) 1.05
Clinical features and preliminary studies of virological correlates of neurocognitive impairment among HIV-infected individuals in Nigeria. J Neurovirol (2012) 1.00
HIV-1 gp120 and drugs of abuse: interactions in the central nervous system. Curr HIV Res (2012) 0.98
A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settings. J Neurovirol (2011) 0.96
Effects of conditional central expression of HIV-1 tat protein to potentiate cocaine-mediated psychostimulation and reward among male mice. Neuropsychopharmacology (2013) 0.92
Global NeuroAIDS roundtable. J Neurovirol (2013) 0.92
Epidemiology of neurodegenerative diseases in sub-Saharan Africa: a systematic review. BMC Public Health (2014) 0.91
HIV-1 nef protein structures associated with brain infection and dementia pathogenesis. PLoS One (2011) 0.91
Most HIV type 1 non-B infections in the Spanish cohort of antiretroviral treatment-naïve HIV-infected patients (CoRIS) are due to recombinant viruses. J Clin Microbiol (2011) 0.90
Efficient transmission and persistence of low-frequency SIVmac251 variants in CD8-depleted rhesus macaques with different neuropathology. J Gen Virol (2012) 0.89
Origin and epidemiological history of HIV-1 CRF14_BG. PLoS One (2011) 0.87
HIV-1 subtype D infections among Caucasians from Northwestern Poland--phylogenetic and clinical analysis. PLoS One (2012) 0.87
HIV-1 Nef in macrophage-mediated disease pathogenesis. Int Rev Immunol (2012) 0.86
Effect of HIV clade differences on the onset and severity of HIV-associated neurocognitive disorders. J Neurovirol (2013) 0.86
Neuronal toxicity in HIV CNS disease. Future Virol (2012) 0.85
Increasing HIV subtype diversity and its clinical implications in a sentinel North American population. Can J Infect Dis Med Microbiol (2013) 0.82
Longitudinal neuropsychological test performance among HIV seropositive individuals in Uganda. J Neurovirol (2013) 0.82
HIV subtype is not associated with dementia among individuals with moderate and advanced immunosuppression in Kampala, Uganda. Metab Brain Dis (2014) 0.82
Profile of the HIV epidemic in Cape Verde: molecular epidemiology and drug resistance mutations among HIV-1 and HIV-2 infected patients from distinct islands of the archipelago. PLoS One (2014) 0.81
Neurology and the Global HIV Epidemic. Semin Neurol (2014) 0.81
Effect of HIV-1 subtypes on disease progression in rural Uganda: a prospective clinical cohort study. PLoS One (2013) 0.81
Prevalence of HIV-Associated Neurocognitive Disorder (HAND) among Patients Attending a Tertiary Health Facility in Northern Nigeria. J Int Assoc Provid AIDS Care (2014) 0.81
Single nucleotide polymorphism in gene encoding transcription factor Prep1 is associated with HIV-1-associated dementia. PLoS One (2012) 0.80
The Impact of HIV Coinfection on Cerebral Malaria Pathogenesis. J Neuroparasitology (2012) 0.79
Enrichment of HIV-1 subtype AD recombinants in a Ugandan cohort of severely septic patients. PLoS One (2012) 0.78
Predicted HIV-1 coreceptor usage among Kenya patients shows a high tendency for subtype d to be cxcr4 tropic. AIDS Res Ther (2012) 0.78
Cerebrospinal fluid can be used for HIV genotyping when it fails in blood. Arq Neuropsiquiatr (2014) 0.78
HIV-miR-H1 evolvability during HIV pathogenesis. Biosystems (2010) 0.77
Neuroimaging abnormalities in clade C HIV are independent of Tat genetic diversity. J Neurovirol (2016) 0.76
The impact of lymphopenia on delirium in ICU patients. PLoS One (2015) 0.75
The inhibition of microRNAs by HIV-1 Tat suppresses beta catenin activity in astrocytes. Retrovirology (2016) 0.75
Suicide risk and prevalence of major depressive disorder (MDD) among individuals infected with HIV-1 subtype C versus B in Southern Brazil. J Neurovirol (2016) 0.75
Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol (1999) 18.82
Updated research nosology for HIV-associated neurocognitive disorders. Neurology (2007) 16.18
Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS (2006) 5.31
Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol (1992) 4.86
The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS (2005) 4.48
Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis (2008) 4.48
Frequency of and risk factors for HIV dementia in an HIV clinic in sub-Saharan Africa. Neurology (2007) 3.14
Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis (2006) 3.03
HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis (2007) 2.87
Full-length sequence and mosaic structure of a human immunodeficiency virus type 1 isolate from Thailand. J Virol (1996) 2.83
The AIDS dementia complex. J Infect Dis (1988) 2.77
Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infect Dis (2002) 2.54
Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis (1999) 2.32
WHO Neuropsychiatric AIDS study, cross-sectional phase II. Neuropsychological and neurological findings. Arch Gen Psychiatry (1994) 2.25
Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology (1998) 2.20
The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia. Proc Natl Acad Sci U S A (2006) 2.13
Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses (1994) 1.99
HIV-1 dynamics in vivo: implications for therapy. Nat Rev Microbiol (2003) 1.94
Pathogenesis of simian immunodeficiency virus encephalitis: viral determinants of neurovirulence. J Virol (1997) 1.86
NMDA receptor activation by HIV-Tat protein is clade dependent. J Neurosci (2008) 1.74
Increased human immunodeficiency virus type 1 (HIV-1) env compartmentalization in the presence of HIV-1-associated dementia. J Virol (2005) 1.65
Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohort. J Acquir Immune Defic Syndr (2007) 1.64
Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. J Acquir Immune Defic Syndr Hum Retrovirol (1999) 1.61
Genetic attributes of cerebrospinal fluid-derived HIV-1 env. Brain (2006) 1.60
Detection of diverse variants of human immunodeficiency virus-1 groups M, N, and O and simian immunodeficiency viruses from chimpanzees by using generic pol and env primer pairs. J Infect Dis (2000) 1.52
Predominance of HIV type 1 subtype G among commercial sex workers from Kinshasa, Democratic Republic of Congo. AIDS Res Hum Retroviruses (2001) 1.48
Benefits and risks of stavudine therapy for HIV-associated neurologic complications in Uganda. Neurology (2009) 1.20
Lentivirus infection in the brain induces matrix metalloproteinase expression: role of envelope diversity. J Virol (2000) 1.12
Correlation between genetic and biological properties of biologically cloned HIV type 1 viruses representing subtypes A, B, and D. AIDS Res Hum Retroviruses (1995) 1.10
Impact of human immunodeficiency virus (HIV) subtypes on HIV-associated neurological disease. J Neurovirol (2007) 1.01
Comparison of mother-to-child transmission rates in Ugandan women with subtype A versus D HIV-1 who received single-dose nevirapine prophylaxis: HIV Network For Prevention Trials 012. J Acquir Immune Defic Syndr (2005) 0.95
Analysis of mutations made during active synthesis or extension of mismatched substrates further define the mechanism of HIV-RT mutagenesis. Biochemistry (2003) 0.83
Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet (2007) 37.69
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84
Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis (2005) 21.08
Laboratory medicine in Africa: a barrier to effective health care. Clin Infect Dis (2005) 12.59
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med (2003) 9.75
Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med (2009) 8.26
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol (2010) 7.56
Circumcision in HIV-infected men and its effect on HIV transmission to female partners in Rakai, Uganda: a randomised controlled trial. Lancet (2009) 6.80
Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS (2007) 5.97
The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr (2004) 5.94
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med (2006) 5.20
Untreated gonococcal and chlamydial infection in a probability sample of adults. JAMA (2002) 5.07
Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS (2004) 4.64
Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS (2009) 4.54
Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study. Lancet (2005) 4.51
The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS (2005) 4.48
Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis (2008) 4.48
Better tests, better care: improved diagnostics for infectious diseases. Clin Infect Dis (2013) 4.27
HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy. AIDS (2011) 4.26
Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA (2005) 4.24
HIV prevention transformed: the new prevention research agenda. Lancet (2011) 4.23
Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet (2010) 4.23
Male circumcision for the prevention of acquisition and transmission of sexually transmitted infections: the case for neonatal circumcision. Arch Pediatr Adolesc Med (2010) 3.84
Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis (2011) 3.78
Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 3.78
Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS One (2009) 3.66
Incident HIV and herpes simplex virus type 2 infection among men in Rakai, Uganda. AIDS (2009) 3.53
Effect of circumcision of HIV-negative men on transmission of human papillomavirus to HIV-negative women: a randomised trial in Rakai, Uganda. Lancet (2011) 3.52
Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis (2005) 3.47
Performance of a commercial, type-specific enzyme-linked immunosorbent assay for detection of herpes simplex virus type 2-specific antibodies in Ugandans. J Clin Microbiol (2004) 3.36
Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis (2004) 3.30
Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention. PLoS One (2011) 3.27
PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology (2013) 3.02
Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis (2005) 3.00
HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr (2012) 2.95
A new model to monitor the virological efficacy of antiretroviral treatment in resource-poor countries. Lancet Infect Dis (2006) 2.92
Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol (2010) 2.91
Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS (2009) 2.88
Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. J Virol (2003) 2.78
Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection: a nested case-control study in Rakai, Uganda. J Infect Dis (2003) 2.72
Male circumcision decreases acquisition and increases clearance of high-risk human papillomavirus in HIV-negative men: a randomized trial in Rakai, Uganda. J Infect Dis (2010) 2.70
A call to action for comprehensive HIV services for men who have sex with men. Lancet (2012) 2.70
Two-year virologic outcomes of an alternative AIDS care model: evaluation of a peer health worker and nurse-staffed community-based program in Uganda. J Acquir Immune Defic Syndr (2009) 2.62
Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission; Rakai, Uganda. AIDS (2003) 2.60
Effect of peer health workers on AIDS care in Rakai, Uganda: a cluster-randomized trial. PLoS One (2010) 2.53
Total lymphocyte count and hemoglobin combined in an algorithm to initiate the use of highly active antiretroviral therapy in resource-limited settings. AIDS (2003) 2.52
Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol (2010) 2.48
Responding to the human resource crisis: peer health workers, mobile phones, and HIV care in Rakai, Uganda. AIDS Patient Care STDS (2008) 2.48
HIV incidence determination in the United States: a multiassay approach. J Infect Dis (2012) 2.47
Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med (2013) 2.44
Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis (2005) 2.43
The etiology of urinary tract infection: traditional and emerging pathogens. Dis Mon (2003) 2.39
Should active recruitment of health workers from sub-Saharan Africa be viewed as a crime? Lancet (2008) 2.31
Prevalence of human immunodeficiency virus-associated cognitive impairment in a group of Hispanic women at risk for neurological impairment. J Neurovirol (2006) 2.27
Comparison of three nucleic acid amplification tests for detection of Chlamydia trachomatis in urine specimens. J Clin Microbiol (2004) 2.26
A programmable prompting device improves adherence to highly active antiretroviral therapy in HIV-infected subjects with memory impairment. Clin Infect Dis (2005) 2.25
Vaginal swabs are appropriate specimens for diagnosis of genital tract infection with Chlamydia trachomatis. J Clin Microbiol (2003) 2.24
Impact of nonoperative treatment, vertebroplasty, and kyphoplasty on survival and morbidity after vertebral compression fracture in the medicare population. J Bone Joint Surg Am (2013) 2.24
High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda. Antivir Ther (2011) 2.20
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol (2011) 2.19
Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Virol (2011) 2.18
Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis. Lancet Infect Dis (2013) 2.18
Incorrect identification of recent HIV infection in adults in the United States using a limiting-antigen avidity assay. AIDS (2014) 2.18
Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria. AIDS (2013) 2.17
Mycoplasma genitalium as a contributor to the multiple etiologies of cervicitis in women attending sexually transmitted disease clinics. Sex Transm Dis (2009) 2.16
Quantitative multiprobe PCR assay for simultaneous detection and identification to species level of bacterial pathogens. J Clin Microbiol (2002) 2.12
Impact of a mHealth intervention for peer health workers on AIDS care in rural Uganda: a mixed methods evaluation of a cluster-randomized trial. AIDS Behav (2011) 2.08
Severe mental illness at ART initiation is associated with worse retention in care among HIV-infected Ugandan adults. Trop Med Int Health (2012) 2.08
Acceptance of routine testing for HIV among adult patients at the medical emergency unit at a national referral hospital in Kampala, Uganda. AIDS Behav (2006) 2.08
Microbial translocation, the innate cytokine response, and HIV-1 disease progression in Africa. Proc Natl Acad Sci U S A (2009) 2.03
Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. Antivir Ther (2006) 2.02
Depression, alcohol use and adherence to antiretroviral therapy in sub-Saharan Africa: a systematic review. AIDS Behav (2012) 2.01
Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the multicenter AIDS cohort study. J Infect Dis (2008) 2.01